27th Jun 2016 11:26
LONDON (Alliance News) - GW Pharmaceuticals PLC Monday announced positive results from its phase III trial of Epidiolex in the treatment of rare childhood epilepsy, Lennox-Gastaut Syndrome.
Shares in GW Pharmaceuticals were up 23% at 624.00 pence Monday following the announcement.
The treatment met its primary endpoint, showing a high statistical significance that Epidiolex reduces the occurrence of drop seizures compared to a placebo.
"We are delighted to announce positive results in this Phase 3 trial of Epidiolex in patients with Lennox-Gastaut syndrome, and particularly pleased that this result is consistent with our recent Phase 3 pivotal data for Epidiolex in Dravet syndrome. We believe that this result further demonstrates that Epidiolex offers the potential to be a new effective therapy within the field of treatment-resistant childhood-onset epilepsies," said Chief Executive Office Justin Gover in a statement.
GW plans to advance Epidiolex towards the submission of a new drug application with the US Food & Drug Administration in the first half of 2017.
By Hana Stewart-Smith; [email protected]; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.